Obese workers are more likely to take more sick days than those of normal weight, according to a study by the Institute for ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

BMI and WC were differentially associated with microvascular and macrovascular complications among patients with type 2 diabetes.

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Patients with obesity, with or without diabetes, lose up to 20% body weight and show A1c reductions with the novel agent maridebart cafraglutide, though nearly all experience GI side effects.

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Experts said that the novel combination of a GLP-1 and amylin analogue will help obese patients with and without diabetes ...

Researchers found that higher relative fat mass (RFM), a measure of visceral body fat, is significantly associated with ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Diginex Limited (“Diginex” or the “Company”) (NASDAQ: DGNX), a leading provider of Sustainability RegTech solutions, today announced its inclusion in the S&P Global ...